Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 20/20 | 0.83 |
| ▸ | WNT1 | P04628 | 10/20 | 0.83 |
| ▸ | CLK2 | P49760 | 5/20 | 0.74 |
| ▸ | CLK3 | P49761 | 5/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14803375 | 0.93 | DYRK1A (0.74) | DYRK1AWNT1CLK2CLK3 | |
| SCHEMBL14804580 | 0.91 | DYRK1A (1.00) | DYRK1AWNT1CLK2CLK3 | |
| SCHEMBL14792563 | 0.90 | DYRK1A (0.76) | DYRK1AWNT1CLK2CLK3 | |
| SCHEMBL14785604 | 0.89 | DYRK1A (0.84) | DYRK1AWNT1CLK2CLK3 | |
| SCHEMBL14803959 | 0.89 | DYRK1A (0.78) | DYRK1AWNT1CLK2CLK3 | |
| SCHEMBL14792212 | 0.88 | DYRK1A (0.74) | DYRK1AWNT1CLK2CLK3 | |
| SCHEMBL14792593 | 0.88 | DYRK1A (0.74) | DYRK1AWNT1CLK2CLK3 | |
| SCHEMBL14792857 | 0.88 | DYRK1A (0.74) | DYRK1AWNT1CLK2CLK3 | |
| SCHEMBL20097399 | 0.88 | DYRK1A (0.64) | DYRK1AWNT1CLK2CLK3 | |
| SCHEMBL14792770 | 0.88 | DYRK1A (0.83) | DYRK1AWNT1CLK2CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669240-B2 | 5-substituted indazole-3-carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-06-02 | — | — | US | claimed |
| US-20180127377-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-05-10 | — | — | US | claimed |
| EP-3119393-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | Samumed, LLC (US) | 2017-01-25 | — | — | EP | claimed |
| WO-2015143380-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | SAMUMED, LLC (US) | 2015-09-24 | — | — | WO | claimed |
| US-20150266825-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2015-09-24 | — | — | US | claimed |
| EP-3528808-B1 | METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS | BIOSPLICE THERAPEUTICS INC (US) | 2021-10-06 | — | — | EP | disclosed |
| US-10669240-B2 | 5-substituted indazole-3-carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20180127377-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-05-10 | — | — | US | disclosed |
| US-20180127377-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-05-10 | — | — | US | disclosed |
| US-9745271-B2 | 5-substituted indazole-3-carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745271-B2 | 5-substituted indazole-3-carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2017-08-29 | — | — | US | disclosed |
| US-20150266825-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2015-09-24 | — | — | US | disclosed |
| US-20150266825-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2015-09-24 | — | — | US | disclosed |
| US-20130079329-A1 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/Beta-CATENIN SIGNALING PATHWAY INHIBITORS | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266825-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, WNT3, WNT1 | DYRK1A 1/4885WNT1 3/4885CLK2 86/4885 |
| US-20180127377-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, WNT3, WNT1 | DYRK1A 1/4885WNT1 3/4885CLK2 86/4885 |
| US-20130079329-A1 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/Beta-CATENIN SIGNALING PATHWAY INHIBITORS | WNT3, WNT1, WNT3A | DYRK1A 733/4885WNT1 2/4885CLK2 1021/4885 |
| US-10669240-B2 | 5-substituted indazole-3-carboxamides and preparation and use thereof | DYRK1A, WNT3, WNT1 | DYRK1A 1/4885WNT1 3/4885CLK2 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.